6,177 followers
👩🔬👨🔬 @NorthwesternU scientists found the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks in refractory metastatic or unresectable soft-tissue #sarcoma and #osteosarcoma. https://t.co/iAnWhRVZ